Deepika Pakianathan - Jun 5, 2024 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
Director
Signature
/s/ Matthew T. Potter, Attorney-in-Fact for Deepika Pakianathan
Stock symbol
KPTI
Transactions as of
Jun 5, 2024
Transactions value $
-$785,027
Form type
4
Date filed
6/7/2024, 07:18 PM
Previous filing
Jun 4, 2024
Next filing
Aug 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale -$444K -464K -57.22% $0.96 347K Jun 5, 2024 See footnote F1, F4
transaction KPTI Common Stock Sale -$4.34K -4.53K -57.21% $0.96 3.39K Jun 5, 2024 See footnote F1, F5
transaction KPTI Common Stock Sale -$115K -117K -33.84% $0.98 229K Jun 6, 2024 See footnote F2, F4
transaction KPTI Common Stock Sale -$1.13K -1.15K -33.83% $0.98 2.24K Jun 6, 2024 See footnote F2, F5
transaction KPTI Common Stock Sale -$218K -229K -100% $0.95 0 Jun 7, 2024 See footnote F3, F4
transaction KPTI Common Stock Sale -$2.13K -2.24K -100% $0.95 0 Jun 7, 2024 See footnote F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.899 to $0.989, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.97 to $1.0302, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9303 to $0.965, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.
F5 The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.